Jordan Gillespie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jordan Gillespie has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Emile Latour
Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
6 shared publications - Jaclyn Roland-McGowan
School of Medicine, Oregon Health & Science University , Portland, OR
4 shared publications - Katelyn Downey
Department of Dermatology, Oregon Health & Science University , Portland, OR
4 shared publications Emile Latour
Department of Dermatology, Oregon Health & Science University, Portland, USA
3 shared publications- Alex Gerardo Ortega-Loayza
Department of Dermatology, Oregon Health and Science University, Portland, USA
2 shared publications Alex Ortega-Loayza
Department of Dermatology, Oregon Health & Science University, Portland, USA
2 shared publications
Latest Publications
- 1 September 2026
- Published by Wiley in Wound Repair and Regeneration
- Vol. 34 (5) , e70222
Partial Healing and Physical Function in Pyoderma Gangrenosum: A Framework for Wound Endpoints
Pyoderma gangrenosum (PG) is a rare, painful ulcerative dermatosis associated with significant functional impairment. Complete w closure is the standard endpoint in wound clinical trials, including PG, but clinically meaningful improvement may occur before total epithelization is achieved. No disease‐specific minimal important difference exists for patient‐reported physical function in PG. We evaluated whether partial healing is associated with differences in physical function and estimated such a threshold using the Skindex‐Mini. This retrospective cohort study included adults with PG receiving dermatologic care at a single academic referral centre between August 2024 and November 2025. Clinical data and patient‐reported outcome measures were obtained from a prospectively maintained PG registry and electronic health records. Healing stage at each visit was categorized as healed, partially healed (≥ 50% reduction in ulcer area) or not healed, and Skindex‐Mini Physical Function scores (0–100 scale, higher scores indicating worse function) were compared using linear mixed‐effects models. The cohort included 80 adults with PG contributing 385 clinical encounters. Physical function scores differed significantly across healing stages ( χ 2 = 39.0; p < 0.001). Compared with unhealed patients, partially healed patients reported better physical function (approximately 17 points lower) and were closer to fully healed patients. A 1‐point improvement in patient global assessment corresponded to an adjusted 20.8‐point improvement in physical function (95% CI, 14.5–27.2; p < 0.001), consistent with distribution‐based estimates. Partially healed patients reported substantially better physical function than unhealed patients, supporting incorporation of patient‐reported physical function and intermediate healing states alongside complete wound closure in PG outcome assessment.
- 1 September 2026
- Published by Wiley in Wound Repair and Regeneration
- Vol. 34 (5) , e70222
Partial Healing and Physical Function in Pyoderma Gangrenosum: A Framework for Wound Endpoints
Pyoderma gangrenosum (PG) is a rare, painful ulcerative dermatosis associated with significant functional impairment. Complete w closure is the standard endpoint in wound clinical trials, including PG, but clinically meaningful improvement may occur before total epithelization is achieved. No disease‐specific minimal important difference exists for patient‐reported physical function in PG. We evaluated whether partial healing is associated with differences in physical function and estimated such a threshold using the Skindex‐Mini. This retrospective cohort study included adults with PG receiving dermatologic care at a single academic referral centre between August 2024 and November 2025. Clinical data and patient‐reported outcome measures were obtained from a prospectively maintained PG registry and electronic health records. Healing stage at each visit was categorized as healed, partially healed (≥ 50% reduction in ulcer area) or not healed, and Skindex‐Mini Physical Function scores (0–100 scale, higher scores indicating worse function) were compared using linear mixed‐effects models. The cohort included 80 adults with PG contributing 385 clinical encounters. Physical function scores differed significantly across healing stages ( χ 2 = 39.0; p < 0.001). Compared with unhealed patients, partially healed patients reported better physical function (approximately 17 points lower) and were closer to fully healed patients. A 1‐point improvement in patient global assessment corresponded to an adjusted 20.8‐point improvement in physical function (95% CI, 14.5–27.2; p < 0.001), consistent with distribution‐based estimates. Partially healed patients reported substantially better physical function than unhealed patients, supporting incorporation of patient‐reported physical function and intermediate healing states alongside complete wound closure in PG outcome assessment.
- 26 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Remote identification of new-onset paediatric atopic dermatitis: a comparison of diagnostic methods from a post hoc analysis of the CASCADE prevention trial
Background: Few validated diagnostic criteria for atopic dermatitis (AD) can diagnose AD without a clinician’s examination, and even fewer are validated in very young children. Recently, the Community-based Assessment of Skin Care, Allergies and Eczema (CASCADE) prevention trial remotely captured parent and caregiver responses to the Childhood Eczema Questionnaire (CEQ) and a Proxy Report of a Clinician AD Diagnosis (PRC-AD) in children ≤ 2 years of age. Objectives: To evaluate the performance of CEQ and PRC-AD for the purpose of remote AD diagnosis. Methods: Data from the CASCADE trial were used to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CEQ or PRC-AD at 12 and 24 months of age in 933 participants with data available for comparison against the reference standard of a clinician’s chart-diagnosis of AD, present in 26.2% (n = 244/933 at 24 months) of the cohort. Clinicians who acted as the reference standard were primary care clinicians or paediatricians who received additional training in diagnosing AD. Results: PRC-AD displayed sensitivity of 65.8% and 71.6%, and specificity of 91.3% and 93.2% at 12 months and 24 months, respectively. It also displayed PPV of 72.5% and 88.3%, and NPV of 88.5% and 82.2% at 12 and 24 months, respectively. In comparison, CEQ showed sensitivity of 46.3% and 50.9%, and specificity of 91.5% and 93.2% at 12 months and 24 months, respectively. It showed PPV of 64.5% and 84.1%, and NPV of 83.5% and 72.8% at 12 months and 24 months, respectively. A lack of proxy-observed or reported itch or rash were the most common reasons for CEQ false-negative cases. Conclusions: PRC-AD performed well for sensitivity, specificity, PPV and NPV, followed by CEQ. This study based in the USA provides new evidence that supports PRC-AD as an adequate approach to identify eczema cases remotely for research in children ≤ 2 years old with access to healthcare.
- 26 August 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
Remote identification of new-onset paediatric atopic dermatitis: a comparison of diagnostic methods from a post hoc analysis of the CASCADE prevention trial
Background: Few validated diagnostic criteria for atopic dermatitis (AD) can diagnose AD without a clinician’s examination, and even fewer are validated in very young children. Recently, the Community-based Assessment of Skin Care, Allergies and Eczema (CASCADE) prevention trial remotely captured parent and caregiver responses to the Childhood Eczema Questionnaire (CEQ) and a Proxy Report of a Clinician AD Diagnosis (PRC-AD) in children ≤ 2 years of age. Objectives: To evaluate the performance of CEQ and PRC-AD for the purpose of remote AD diagnosis. Methods: Data from the CASCADE trial were used to calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CEQ or PRC-AD at 12 and 24 months of age in 933 participants with data available for comparison against the reference standard of a clinician’s chart-diagnosis of AD, present in 26.2% (n = 244/933 at 24 months) of the cohort. Clinicians who acted as the reference standard were primary care clinicians or paediatricians who received additional training in diagnosing AD. Results: PRC-AD displayed sensitivity of 65.8% and 71.6%, and specificity of 91.3% and 93.2% at 12 months and 24 months, respectively. It also displayed PPV of 72.5% and 88.3%, and NPV of 88.5% and 82.2% at 12 and 24 months, respectively. In comparison, CEQ showed sensitivity of 46.3% and 50.9%, and specificity of 91.5% and 93.2% at 12 months and 24 months, respectively. It showed PPV of 64.5% and 84.1%, and NPV of 83.5% and 72.8% at 12 months and 24 months, respectively. A lack of proxy-observed or reported itch or rash were the most common reasons for CEQ false-negative cases. Conclusions: PRC-AD performed well for sensitivity, specificity, PPV and NPV, followed by CEQ. This study based in the USA provides new evidence that supports PRC-AD as an adequate approach to identify eczema cases remotely for research in children ≤ 2 years old with access to healthcare.
- Open Access
- 25 July 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (5) , 945-957
Is Acanthosis Nigricans a Marker for Metabolic Syndrome? A Systematic Review
Background/Objective Certain skin conditions are proven indicators of underlying systemic disease. Specifically, acanthosis nigricans (AN) is commonly associated with type 2 diabetes and insulin resistance. However, AN may also be a marker of metabolic syndrome (MS). MS is linked to several health conditions leading to death. Therefore, early identification of MS is crucial in preventing disease progression. While AN may provide a visual cue for MS risk, its utility as a clinical screening tool remains underexplored. To address this, we conducted a systematic review to evaluate the association between AN and MS. Methods We systematically searched PubMed, Embase, and Cochrane Review using the term “acanthosis nigricans,” identifying 656 articles, including 322 case reports, that reported AN in association with at least one MS criteria, as defined by the American Heart Association. Article quality was determined using the Strength of Recommendation Taxonomy (SORT) grading system. Results Across the 656 included articles, the unweighted mean proportion of study participants with AN was 70.8% (standard deviation of 34.9%), reflecting that many studies evaluated broader patient populations in which AN was one of several conditions assessed. Of all MS criteria, insulin resistance showed the highest mean prevalence of AN at 72.6%. Within all articles, 65.9% met more than one MS criterion, with co-occurrence of insulin resistance and increased body mass being the most common combination (25.5%). In a subanalysis of non-case-report studies in which all participants had AN, 67.4% met the full criteria for MS, with increased body mass being the most frequently reported individual criterion (89.7% of cases). Conclusions This review provides a better estimate of AN observed in individuals with MS or in those at risk for MS. Integrating dermatologic examination for AN into primary care and preventive health may improve early detection of MS, reduce costs and unnecessary testing, and promote targeted interventions. Educational efforts are needed to increase clinician awareness of the association between AN and MS.
- 25 July 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (5) , 945-957
Open AccessIs Acanthosis Nigricans a Marker for Metabolic Syndrome? A Systematic Review
Background/Objective Certain skin conditions are proven indicators of underlying systemic disease. Specifically, acanthosis nigricans (AN) is commonly associated with type 2 diabetes and insulin resistance. However, AN may also be a marker of metabolic syndrome (MS). MS is linked to several health conditions leading to death. Therefore, early identification of MS is crucial in preventing disease progression. While AN may provide a visual cue for MS risk, its utility as a clinical screening tool remains underexplored. To address this, we conducted a systematic review to evaluate the association between AN and MS. Methods We systematically searched PubMed, Embase, and Cochrane Review using the term “acanthosis nigricans,” identifying 656 articles, including 322 case reports, that reported AN in association with at least one MS criteria, as defined by the American Heart Association. Article quality was determined using the Strength of Recommendation Taxonomy (SORT) grading system. Results Across the 656 included articles, the unweighted mean proportion of study participants with AN was 70.8% (standard deviation of 34.9%), reflecting that many studies evaluated broader patient populations in which AN was one of several conditions assessed. Of all MS criteria, insulin resistance showed the highest mean prevalence of AN at 72.6%. Within all articles, 65.9% met more than one MS criterion, with co-occurrence of insulin resistance and increased body mass being the most common combination (25.5%). In a subanalysis of non-case-report studies in which all participants had AN, 67.4% met the full criteria for MS, with increased body mass being the most frequently reported individual criterion (89.7% of cases). Conclusions This review provides a better estimate of AN observed in individuals with MS or in those at risk for MS. Integrating dermatologic examination for AN into primary care and preventive health may improve early detection of MS, reduce costs and unnecessary testing, and promote targeted interventions. Educational efforts are needed to increase clinician awareness of the association between AN and MS.
- 24 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2085-2088
Initial psychometric validation of the Caregiver Atopic Dermatitis Control Tool
The Atopic Dermatitis Control Tool (ADCT) is a validated six-item tool used in clinical trials to assess eczema control in adolescents and adults. Two versions of the ADCT were recently developed using a US Food and Drug Administration-recommended methodology. One is intended for use with caregivers of children aged 6 months to 11 years (the Caregiver ADCT; score range 0–24; higher scores indicate worse control; recall period the past 7 days). The other, the Child Eczema Control Tool (ECT), is intended for use with children aged 8 to 11 years. We conducted the first psychometric validation of the Caregiver ADCT (first 100 caregivers recruited), which demonstrated no floor or ceiling effects in response distributions, except for a floor effect for ‘sleep-trouble nights’ (47% selected the least severe option; n = 47/100). There were strong inter-item correlations (r ≥ 0.57; P < 0.001) and construct validity (r ≥ 0.59; P < 0.001), consistent with a priori hypotheses. The Caregiver ADCT showed strong internal consistency (Cronbach’s α = 0.92, 95% confidence interval 0.90–0.94). A score ≥ 7 was identified as the optimal threshold for identifying children whose eczema was ‘not in control’.
- 24 July 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 51 (11) , 2085-2088
Initial psychometric validation of the Caregiver Atopic Dermatitis Control Tool
The Atopic Dermatitis Control Tool (ADCT) is a validated six-item tool used in clinical trials to assess eczema control in adolescents and adults. Two versions of the ADCT were recently developed using a US Food and Drug Administration-recommended methodology. One is intended for use with caregivers of children aged 6 months to 11 years (the Caregiver ADCT; score range 0–24; higher scores indicate worse control; recall period the past 7 days). The other, the Child Eczema Control Tool (ECT), is intended for use with children aged 8 to 11 years. We conducted the first psychometric validation of the Caregiver ADCT (first 100 caregivers recruited), which demonstrated no floor or ceiling effects in response distributions, except for a floor effect for ‘sleep-trouble nights’ (47% selected the least severe option; n = 47/100). There were strong inter-item correlations (r ≥ 0.57; P < 0.001) and construct validity (r ≥ 0.59; P < 0.001), consistent with a priori hypotheses. The Caregiver ADCT showed strong internal consistency (Cronbach’s α = 0.92, 95% confidence interval 0.90–0.94). A score ≥ 7 was identified as the optimal threshold for identifying children whose eczema was ‘not in control’.
- Open Access
- 20 July 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 98
Recurrence after healing in pyoderma gangrenosum: a prospective registry-based cohort study
- 20 July 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 98
Open AccessRecurrence after healing in pyoderma gangrenosum: a prospective registry-based cohort study
- Open Access
- 19 June 2026
- Published by Elsevier in JID Innovations
- Vol. 6 (5) , 100500
Lesional pruritus in pyoderma gangrenosum: Present but not predominant
- 19 June 2026
- Published by Elsevier in JID Innovations
- Vol. 6 (5) , 100500
Open AccessLesional pruritus in pyoderma gangrenosum: Present but not predominant
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.
- 11 May 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (10) , 937-940
Generalized Bullous Fixed Drug Eruption due to Clopidogrel Hypersensitivity Successfully Treated Using the Jefferson Procedure
Generalized bullous fixed drug eruption (GBFDE) is a rare variant of fixed drug eruption that is known to clinically mimic Stevens‐Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Numerous medications have been reported to cause GBFDE, including antiplatelet agents like ticagrelor, but few reports exist linking this reaction to clopidogrel specifically. We report a case of a medically complex 80‐year‐old male who was found to have clopidogrel hypersensitivity manifesting as GBFDE based on clinical characteristics and pathology. He was successfully treated using the Jefferson desensitization protocol, which was developed by cardiologists to enable continuation of clopidogrel. While clopidogrel hypersensitivity reactions are well‐reported, there is a shortage of dermatology literature characterizing the clinical characteristics of these rashes and highlighting the use of the Jefferson desensitization protocol. This case reports on an etiology for GBFDE that is rarely observed and emphasizes the importance of histopathology when differentiating this entity from SJS/TEN. It also reports the successful use of the Jefferson protocol for GBFDE secondary to clopidogrel hypersensitivity.
- Open Access
- 28 April 2026
- Published by Elsevier in SSRN Electronic Journal
Recurrence after Healing in Pyoderma Gangrenosum: Prospective Five-Year Registry Data
Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis with potential for relapse after healing, yet recurrence in real-world settings remains unknown. We aimed to evaluate recurrence patterns to inform clinical practice and future research.Methods: Data were abstracted from a uniquely, prospectively maintained PG registry. A cohort of patients with PG seen between December 2019 and March 2026 who healed within this timeframe was identified. Two subgroups were then created: those who remained healed, and those who had a recurrence. Descriptive statistics summarized recurrence characteristics, Kaplan-Meier methods estimated a cumulative incidence of recurrence, and Cox proportional hazards modeling identified predictors of recurrence.Findings: Of 116 patients with healed PG, 41 (35·3%) experienced a recurrence, generating a recurrence proportion of 35·3% (95% Confidence Interval [CI]: 26·7%-44·8%). Nominal associations with recurrence on univariable analysis included history of diabetes mellitus (hazard ratio [HR] 2·12, 95% CI: 1·13-3·97, p=0·019) and ever-smoking (HR 1·82, 95% CI: 0·98-3·37, p=0·058). Baseline characteristics differing between recurrence and non-recurrence groups included age (p=0·033), history of diabetes (p=0·006), and ulcer age at presentation (p=0·046). Cumulative PG recurrence risk was calculated as 27% (95% CI: 18·1-35) and 41·3% (95% CI: 30·4–50·5) at one and five years respectively. In an exploratory analysis restricted to classic and peristomal subtypes, peristomal PG had a higher hazard of recurrence compared to classic PG (adjusted HR 2·10, 95% CI: 0·95-4·65, p=0·069).Interpretation: PG recurred in approximately a third of patients. A history of diabetes showed a borderline association with recurrence, while the univariable signal for smoking was attenuated after adjustment. Recurrence risk remains elevated five years after initial healing, and peristomal PG is associated with higher recurrence rates, suggesting that maintenance therapy is necessary after achieving ulcer closure. Future work will focus on individual recurrence predictors.
- 28 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessRecurrence after Healing in Pyoderma Gangrenosum: Prospective Five-Year Registry Data
Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis with potential for relapse after healing, yet recurrence in real-world settings remains unknown. We aimed to evaluate recurrence patterns to inform clinical practice and future research.Methods: Data were abstracted from a uniquely, prospectively maintained PG registry. A cohort of patients with PG seen between December 2019 and March 2026 who healed within this timeframe was identified. Two subgroups were then created: those who remained healed, and those who had a recurrence. Descriptive statistics summarized recurrence characteristics, Kaplan-Meier methods estimated a cumulative incidence of recurrence, and Cox proportional hazards modeling identified predictors of recurrence.Findings: Of 116 patients with healed PG, 41 (35·3%) experienced a recurrence, generating a recurrence proportion of 35·3% (95% Confidence Interval [CI]: 26·7%-44·8%). Nominal associations with recurrence on univariable analysis included history of diabetes mellitus (hazard ratio [HR] 2·12, 95% CI: 1·13-3·97, p=0·019) and ever-smoking (HR 1·82, 95% CI: 0·98-3·37, p=0·058). Baseline characteristics differing between recurrence and non-recurrence groups included age (p=0·033), history of diabetes (p=0·006), and ulcer age at presentation (p=0·046). Cumulative PG recurrence risk was calculated as 27% (95% CI: 18·1-35) and 41·3% (95% CI: 30·4–50·5) at one and five years respectively. In an exploratory analysis restricted to classic and peristomal subtypes, peristomal PG had a higher hazard of recurrence compared to classic PG (adjusted HR 2·10, 95% CI: 0·95-4·65, p=0·069).Interpretation: PG recurred in approximately a third of patients. A history of diabetes showed a borderline association with recurrence, while the univariable signal for smoking was attenuated after adjustment. Recurrence risk remains elevated five years after initial healing, and peristomal PG is associated with higher recurrence rates, suggesting that maintenance therapy is necessary after achieving ulcer closure. Future work will focus on individual recurrence predictors.
- 22 August 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (2) , 539-541
The Human Factor: Unpacking Biopsy Decision Variability that Artificial Intelligence Cannot Predict
- 22 August 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (2) , 539-541
The Human Factor: Unpacking Biopsy Decision Variability that Artificial Intelligence Cannot Predict
- 17 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (1) , 277-279
The Melanoma Toolkit for Early Detection Improves Accuracy but Fails to Improve the Number Needed to Biopsy
- 17 July 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (1) , 277-279
The Melanoma Toolkit for Early Detection Improves Accuracy but Fails to Improve the Number Needed to Biopsy